Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Kim, D.W, (D. W.); Chul-Cho, B. (B.); Perez-Gracia, J.L. (Jose Luis); Han, J.Y. (J. Y.); Dubos-Arvis, C. (C.); Majem-Tarruella, M. (Margarita); Forster, M. (M.); Monnet, I. (I.); Novello, S. (S.); Szalai, Z. (Z.); Gubens, M.A. (M. A.); Su, W.C. (W. C.); Ceresoli, G.L. (G. L.); Samkari, A. (A.); Jensen, E.H. (E. H.); Lubiniecki, G.M (G. M.); Baas, P. (P.)

Keywords:

Improved OS
Docetaxel

Issue Date:

2018

Publisher:

Elsevier

ISSN:

0923-7534

Citation:

Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Kim, D.W, (D. W.); et al. "Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro". Annals of oncology. 29 (Supl. 10), 2018, 42

Abstract

In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We present long-term results overall, in pts who completed 35 cycles (∼2 y) of pembro, and in pts who received a second course of pembro.

URI:

https://hdl.handle.net/10171/65452

DOI:

10.1093/annonc/mdy511.003

Appears in Collections:

DA - CUN - Oncología médica - Artículos de revista

Files in This Item: